Plain-English translation of NCT07665723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called designed to treat moderately to severely active ulcerative colitis. Researchers want to understand how this medication works in your body and, importantly, whether it affects how your body processes other medicines you might be taking. This information will help doctors know if it's safe to use this treatment alongside other drugs.
When a new medication is introduced, doctors need to understand if it interferes with how your body breaks down and uses other drugs — especially medicines you may already be taking for other conditions. This study fills that gap by examining these potential interactions before the medication is more widely available.
You likely qualify if…
You likely don't qualify if…
You will receive a special combination of medicines (called a CYP cocktail) that your body processes in a specific way, and researchers will measure how your body handles these drugs. Then you'll receive doses of the new medication () and the researchers will repeat the measurements to see if the new treatment changes how your body processes those other drugs. There is also an optional phase where you can continue receiving the new medication for a longer period to monitor how well it works for your ulcerative colitis.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States
Germany
United Kingdom